Serac Healthcare and the University of Exeter are highlighting that the first patient has been scanned with a novel molecular SPECT imaging agent, technetium-99m (Tc-99m) maraciclatide.
This is part of a phase II study titled "PRospective Evaluation of Interstitial Lung Disease progression with quantitative CT (PREDICT-ILD)." The study's goal is to evaluate the efficacy of quantitative CT for the detection of interstitial lung disease progression.
A substudy has also started, evaluating Tc-99m maraciclatide as an imaging marker for disease prognostication in a subset of PREDICT-ILD participants. PREDICT-ILD is currently recruiting patients across three National Health Service (NHS) sites in the southwest: North Bristol NHS Trust (NBT), Royal United Hospitals (RUH) NHS Foundation Trust, and Royal Devon University Healthcare NHS Foundation Trust.
Co-chief investigators on the study, which is being run by the university, are Chris Scotton, PhD, and Giles Dixon, MD. PREDICT-ILD is majority funded by the Wellcome Trust GW4-CAT HP PhD Programme for Health Professionals.
